全文获取类型
| 收费全文 | 10566篇 |
| 免费 | 2893篇 |
| 国内免费 | 242篇 |
专业分类
| 耳鼻咽喉 | 659篇 |
| 儿科学 | 284篇 |
| 妇产科学 | 226篇 |
| 基础医学 | 198篇 |
| 口腔科学 | 315篇 |
| 临床医学 | 1704篇 |
| 内科学 | 2493篇 |
| 皮肤病学 | 519篇 |
| 神经病学 | 1177篇 |
| 特种医学 | 540篇 |
| 外科学 | 3118篇 |
| 综合类 | 43篇 |
| 现状与发展 | 2篇 |
| 预防医学 | 797篇 |
| 眼科学 | 352篇 |
| 药学 | 120篇 |
| 中国医学 | 2篇 |
| 肿瘤学 | 1152篇 |
出版年
| 2024年 | 75篇 |
| 2023年 | 509篇 |
| 2022年 | 142篇 |
| 2021年 | 296篇 |
| 2020年 | 731篇 |
| 2019年 | 215篇 |
| 2018年 | 662篇 |
| 2017年 | 627篇 |
| 2016年 | 783篇 |
| 2015年 | 696篇 |
| 2014年 | 946篇 |
| 2013年 | 1062篇 |
| 2012年 | 353篇 |
| 2011年 | 287篇 |
| 2010年 | 638篇 |
| 2009年 | 851篇 |
| 2008年 | 327篇 |
| 2007年 | 196篇 |
| 2006年 | 300篇 |
| 2005年 | 169篇 |
| 2004年 | 124篇 |
| 2003年 | 99篇 |
| 2002年 | 96篇 |
| 2001年 | 179篇 |
| 2000年 | 119篇 |
| 1999年 | 182篇 |
| 1998年 | 254篇 |
| 1997年 | 272篇 |
| 1996年 | 318篇 |
| 1995年 | 287篇 |
| 1994年 | 179篇 |
| 1993年 | 128篇 |
| 1992年 | 131篇 |
| 1991年 | 135篇 |
| 1990年 | 74篇 |
| 1989年 | 129篇 |
| 1988年 | 103篇 |
| 1987年 | 79篇 |
| 1986年 | 87篇 |
| 1985年 | 90篇 |
| 1984年 | 91篇 |
| 1983年 | 75篇 |
| 1982年 | 75篇 |
| 1981年 | 52篇 |
| 1980年 | 54篇 |
| 1978年 | 46篇 |
| 1977年 | 47篇 |
| 1976年 | 34篇 |
| 1975年 | 44篇 |
| 1972年 | 35篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
2.
3.
4.
5.
Joseph F. Levy Rahul Khairnar Alexander V. Louie Timothy N. Showalter C. Daniel Mullins Mark V. Mishra 《Practical radiation oncology》2019,9(2):e172-e179
Purpose
A hydrogel rectal spacer (HRS) is a medical device that is approved by the U.S. Food and Drug Administration to increase the separation between the prostate and rectum. We conducted a cost-effectiveness analysis of HRS use for reduction in radiation therapy (RT) toxicities in patients with prostate cancer (PC) undergoing external beam RT (EBRT).Methods and Materials
A multistate Markov model was constructed from the U.S. payer perspective to examine the cost-effectiveness of HRS in men with localized PC receiving EBRT (EBRT alone vs EBRT + HRS). The subgroups analyzed included site of HRS placement (hospital outpatient, physician office, ambulatory surgery center) and proportion of patients with good baseline erectile function (EF). Data on EF, gastrointestinal and genitourinary toxicities incidence, and potential risks associated with HRS implantation were obtained from a recently published randomized clinical trial. Health utilities and costs were derived from the literature and the 2018 Physician Fee Schedule and were discounted 3% annually. Quality-adjusted life years (QALYs) and costs were modeled for a 5-year period from receipt of RT. Probabilistic sensitivity analysis and value-based threshold analyses were conducted.Results
The per-patient 5-year incremental cost for spacers administered in a hospital outpatient setting was $3578, and the incremental effectiveness was 0.0371 QALYs. The incremental cost-effectiveness ratio was $96,440/QALY for patients with PC undergoing HRS insertion in a hospital and $39,286/QALY for patients undergoing HRS insertion in an ambulatory facility. For men with good baseline EF, the incremental cost-effectiveness ratio was $35,548/QALY and $9627/QALY in hospital outpatient and ambulatory facility settings, respectively.Conclusions
Based on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision-making. 相似文献6.
7.
8.
9.